Inhibition of terminal complement activation in severe Shiga toxin-associated HUS - perfect example for a fast track from bench to bedside

EMBO Mol Med. 2011 Nov;3(11):617-9. doi: 10.1002/emmm.201100169. Epub 2011 Sep 23.

Authors

Dorothea Orth-Höller¹, Magdalena Riedl, Reinhard Würzner

Affiliation

¹ Division of Hygiene & Med. Microbiology, Innsbruck Medical University, Innsbruck, Austria.

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Complement Activation / drug effects*
Complement C5 / antagonists & inhibitors*
Complement C5 / immunology
Enterohemorrhagic Escherichia coli / immunology*
Enterohemorrhagic Escherichia coli / physiology
Hemolytic-Uremic Syndrome / drug therapy*
Hemolytic-Uremic Syndrome / immunology*
Hemolytic-Uremic Syndrome / microbiology
Humans
Shiga Toxin / immunology*

Substances

Antibodies, Monoclonal, Humanized
Complement C5
Shiga Toxin
eculizumab